Hospital investigating whether Baxter's Heparin had role in death of two patients
Baxter International Inc. said medical care providers at a hospital in Delaware and U.S. health officials are investigating whether the deaths of two patients are linked to a brand of heparin blood thinner Baxter sells in intravenous bags. Use of Baxter's heparin, a diluted form in pre-mixed bags used for a variety of blood thinning purposes, has been suspended by officials at Beebe Medical Center in Lewes, DE, since Friday. Adverse reactions were reported in five patients who had problems that included internal bleeding in the brain.
- Senators Hear How Two-Midnight Rule Harms Patients, Hospitals
- 3 Management Lessons from a Supermarket Debacle
- Handshaking Spreads Germs. Get Over It.
- Healthcare Costs Start With What We Eat
- Hospitals Likely to Outsource ICD-10 at Launch
- IOM Identifies GME Problems, Calls for Finance Changes
- CMS Confirms ICD-10 Deadline
- Anatomy of 3 Health System Rebranding Efforts
- Premium Subsidy Fight Creating Uncertainty for Hospitals, Health Plans
- Medicare Advantage Carriers See 'No Choice' But to Accept Cuts